Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Why Biogen Stock Popped as Much as 37.1% This Week
05:23pm, Friday, 30'th Sep 2022 The Motley Fool
The company's Alzheimer's drug is showing promise in clinical trials.
Stocks moving in after hours: FedEx, Nvidia, Intel, AMD, Biogen
05:18pm, Friday, 30'th Sep 2022
Yahoo Finance Live's Seana Smith looks at several stocks trending in the after-hours trading session.
Why Biogen Stock Popped as Much as 37.1% This Week
01:23pm, Friday, 30'th Sep 2022
The company's Alzheimer's drug is showing promise in clinical trials.
The 5 Best—and 5 Worst—Nasdaq 100 Stocks in Third Quarter
12:52pm, Friday, 30'th Sep 2022
Constellation Energy was the best performer in the Nasdaq 100 for the third quarter. Okta was the worst.
Eisai, Biogen And Alzheimer's: Never Say Die, Lecanemab To The Rescue
11:56am, Friday, 30'th Sep 2022
Eisai and Biogen get another chance. Still not a cure, but a big step forward even though it's still just a glimmer of hope for Alzheimer's sufferers. The big news is that lecanemab produced a measura
Biogen and Alzheimer's drug development companies surge on positive clinical data
11:21am, Friday, 30'th Sep 2022
Alzheimer's drug development companies have been handed a boost in share prices this week following data for the pioneering treatment lecanemab. Positive late-stage clinical data announced by Biogen I
Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)
11:00am, Friday, 30'th Sep 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BIIB
Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review
10:48am, Friday, 30'th Sep 2022
The major indexes fell, with the S&P 500 breaking below bear market lows. Biogen soared on an Alzheimer's drug while Nike dived.
9 Stocks Turned $10,000 Into $129,224 In 9 Months
08:00am, Friday, 30'th Sep 2022
It's a tough S&P 500 stock market to make money on. But some investors are still finding a way to do it.
Biotech Stock Roundup: BIIB's AD Drug Data & REGN, IONS, VRTX's Updates
04:12pm, Thursday, 29'th Sep 2022 Zacks Investment Research
Regulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week.
LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data
01:39pm, Thursday, 29'th Sep 2022 Zacks Investment Research
The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.
Stock Market News for Sep 29, 2022
01:10pm, Thursday, 29'th Sep 2022 Zacks Investment Research
Wall Street closed sharply higher on Wednesday rebounding from a six-day losing streak.
Will Medicare cover Eisai and Biogen's promising new Alzheimer's therapy if it's approved?
12:49pm, Thursday, 29'th Sep 2022 MarketWatch
Some analysts are tempering their expectations of lecanemab until they get a better idea if Medicare will pay for the drug.
Teamwork Pays: Biogen, Eisai Announce Positive Results For Alzheimer's Drug
12:09pm, Thursday, 29'th Sep 2022
Biogen and Eisai announce positive clinical results for lecanemab, a novel treatment for Alzheimer's disease. Lecanemab continues the collaboration between the companies, after the controversial appro
Biogen's Alzheimer's drug could generate ‘$8 billion in peak sales': Analyst
10:40am, Thursday, 29'th Sep 2022
Mizuho Americas Senior Biotech Analyst Salim Syed joins Yahoo Finance Live anchors Julie Hyman and Brad Smith to discuss encouraging Phase 3 data from Biogen's Alzheimer's treatment lecanemab, how man
